Professor Robert Storey
BSc, BM, DM, FRCP, FESC
Clinical Medicine, School of Medicine and Population Health
Professor of Clinical Cardiology
+44 114 305 2055
Full contact details
Clinical Medicine, School of Medicine and Population Health
Northern General Hospital
Herries Road
Sheffield
S5 7AU
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I joined the University of Sheffield in 2002 as a Senior Clinical Lecturer in Cardiology and subsequently became Professor of Cardiology in January 2011. I am Clinical Lead for the Cardiovascular Disease research theme and Director of the Cardiovascular Research Unit. I am also Academic Director for the Cardiology and Cardiothoracic Surgery Directorate and an Honorary Consultant Cardiologist with Sheffield Teaching Hospitals National Health Service Foundation Trust.
I have a special interest in atherothrombosis and antithrombotic therapy in the management of ischaemic heart disease, including coronary intervention. I was Chair of the European Society of Cardiology (ESC) Working Group on Thrombosis 2012-2014 and have been a member of 4 Task Forces for ESC Guidelines as well as author of many ESC position papers. I received a BSc Hons in biochemistry from the University of York, UK, in 1985 before going on to obtain my medical degree (BM) from the University of Southampton in 1989. After completing general professional training, I trained in the fields of Cardiology and General (Internal) Medicine at Queen´s Medical Centre in Nottingham, completing specialist training in both fields in 2001.
During that time, I developed a keen interest in thrombosis research, studying platelet biology and pharmacology, conducting clinical research studies in patients with cardiovascular disease and obtaining a postgraduate degree in research (DM) from the University of Nottingham.
I have been an Executive/Steering Committee member of numerous international clinical trials such as the PLATO, PEGASUS-TIMI 54, AUGUSTUS and COMPLETE studies and am currently a member of the steering committees for the RAPID-CTCA, SENIOR-RITA, CLEAR-SYNERGY and other studies.
- Research interests
-
My principal research area is atherothrombosis. My particular interests are:
- platelet pharmacology
- relationships between inflammation and atherothrombosis
- fibrin clot properties and thrombotic risk
- cardiovascular clinical trials
- clinical practice guidelines
Current projects
Numerous projects in the areas of antithrombotic therapy and acute coronary syndromes.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. European Heart Journal, 39(13), 1078-1085. View this article in WRRO
- Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology, 67(10), 1145-1154. View this article in WRRO
- Platelet P2Y 12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(12), 2562-2570. View this article in WRRO
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 372(19), 1791-1800.
- Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(11), 1016-1027.
- Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.. Cardiovasc Res, 102(3), 429-435.
- Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.. Eur Heart J, 32(23), 2945-2953.
- Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.. Arterioscler Thromb Vasc Biol, 30(12), 2385-2391.
- Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol, 56(18), 1456-1462.
- Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.. J Am Coll Cardiol, 56(3), 185-193.
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEW ENGL J MED, 361(11), 1045-1057.
- Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.. Circulation, 119(1), 116-122.
All publications
Journal articles
- Long-term efficacy of concomitant surgical ablation for atrial fibrillation with cardiac surgery. European Heart Journal, 45(Supplement_1).
- Virtual physiological analysis of non-culprit disease in patients with STEMI and multivessel disease: a substudy of the COMPLETE trial. European Heart Journal, 45(Supplement_1).
- Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy. European Heart Journal, 45(Supplement_1).
- Detection of chronic obstructive pulmonary disease and frequency of cardiopulmonary events in patients with a significant smoking history hospitalised for acute myocardial infarction. European Heart Journal, 45(Supplement_1).
- Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy. European Heart Journal, 45(Supplement_1).
- Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 22(9), 471-482.
- Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation, 150(4), 317-335.
- Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction. American Heart Journal.
- Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial. The American Journal of Medicine.
- The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome. International Journal of Cardiology, 131940-131940.
- SYNERGY—Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry. The American Journal of Cardiology.
- Antiplatelet Therapy After PCI: The Art and Science of De-Escalation. Circulation, 149(8), 601-604.
- [2023 ESC Guidelines for the management of acute coronary syndromes].. G Ital Cardiol (Rome), 25(2 Suppl 2), e1-e112.
- 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 13(1), 55-161.
- Drug therapies for stroke prevention. British Journal of Cardiology.
- Impact of patient-reported frailty on cardiovascular outcomes in elderly patients with non-ST-elevation myocardial infarction. European Heart Journal, 44(Supplement_2).
- Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. European Heart Journal, 44(Supplement_2).
- Interactions between aspirin and ticagrelor during experimental human endotoxaemia. European Heart Journal, 44(Supplement_2).
- Lipoprotein(a) and Benefit of Antiplatelet Therapy. JACC: Advances, 2(9), 100675-100675.
- TCT-623 Effects of Complete Revascularization in Relation to Left Ventricular Function in Patients With STEMI and Multivessel Disease: Data from the COMPLETE Randomized trial. Journal of the American College of Cardiology, 82(17), B250-B251.
- Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial. Circulation: Cardiovascular Interventions, 16(9).
- Early computed tomography coronary angiography and preventative treatment in patients with suspected acute coronary syndrome: A secondary analysis of the RAPID-CTCA trial. American Heart Journal, 266, 138-148.
- Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. American Heart Journal.
- 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal, 44(38), 3720-3826.
- Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial. International Journal of Cardiology, 131291-131291.
- Coronary Atherosclerotic Plaque Activity and Future Coronary Events. JAMA Cardiology, 8(8), 755-755.
- Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.. Circulation, 147(25), 1933-1944.
- Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants. Journal of the American College of Cardiology, 81(19), 1933-1936.
- Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. European Heart Journal - Cardiovascular Pharmacotherapy, 9(5), 462-496.
- Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease. Cardiovascular Research, 119(7), 1596-1605.
- Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology, 149, 107145-107145.
- Intraoperative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting. JTCVS Open.
- Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. Platelets, 34(1).
- Prolonged Inflammatory Response Post-Hypoglycemia: Mechanistic Insights Into the Relationship Between Low Glucose and Cardiovascular Risk. Diabetes, 71(12), 2483-2485.
- Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.. J Am Coll Cardiol, 80(18), 1735-1747.
- Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Cardiovascular Research, 118(Supplement_2).
- Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 43(Supplement_2).
- TCT-36 Complete Revascularization Versus Culprit Lesion–Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial. Journal of the American College of Cardiology, 80(12), B15-B15.
- TCT-35 Effects of Complete Revascularization According to Age in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel: Insights From the COMPLETE Trial. Journal of the American College of Cardiology, 80(12), B15-B15.
- 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal, 43(39), 3826-3924.
- Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review. Journal of Thoracic Disease, 14(8), 3030-3044.
- Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT.. Health Technol Assess, 26(37), 1-114.
- P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.. Nat Rev Cardiol.
- Antithrombotic Drug Removal from Whole Blood Using Haemoadsorption with a Porous Polymer Bead Sorbent.. Eur Heart J Cardiovasc Pharmacother.
- Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial. European Heart Journal: Acute Cardiovascular Care. View this article in WRRO
- Plaque Burden and 1-Year Outcomes in Acute Chest Pain. JACC: Cardiovascular Imaging.
- Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention : insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions.
- THE PROGNOSTIC VALUE OF PLAQUE IN PATIENTS WITH ACUTE CHEST PAIN. Journal of the American College of Cardiology, 79(9), 1220.
- CLINICAL CORRELATES OF ISCHEMIC AND BLEEDING RISK IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION TREATED WITH EXTENDED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR 60 MG: INSIGHTS FROM ALETHEIA, A MULTI-COUNTRY OBSERVATIONAL STUDY. Journal of the American College of Cardiology, 79(9), 1140.
- SYNERGY- EVEROLIMUS ELUTING STENT WITH A BIOABSORBABLE POLYMER IN ST ELEVATION MYOCARDIAL INFARCTION- CLEAR SYNERGY OASIS-9 TRIAL. Journal of the American College of Cardiology, 79(9), 575.
- THROMBOINFLAMMATORY RESPONSE TO ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY LEADS TO IMPAIRED PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 79(9), 1094-1094.
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. Nat Rev Cardiol.
- A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. Cardiovascular Diabetology, 20(1).
- Abstract 13221: The Biomarker-Based ABC-ACS (Age, Biomarkers, Clinical History) Score Can Predict Major Bleeding Better Than Other Contemporary Scores in Patients on Dual Antiplatelet Therapy After Coronary Revascularization: Results of a Large Derivation and Validation Study. Circulation, 144(Suppl_1), a13221-a13221.
- Abstract 12512: Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial. Circulation, 144(Suppl_1), a12512-a12512.
- TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 78(19), B82-B83.
- Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. European Heart Journal, 42(Supplement_1).
- Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ: British Medical Journal, 374. View this article in WRRO
- Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events.. Eur Heart J.
- Ticagrelor monotherapy in CKD: better safety at what price?. Eur Heart J.
- Selatogrel and other P2Y12 inhibitors’ putative off-target effects. Journal of Cardiovascular Pharmacology, Publish Ahead of Print.
- Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial. Journal of the American Heart Association, 10(17).
- Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 42(31), 2973-2985.
- Ticagrelor : clinical development and future potential. Reviews in Cardiovascular Medicine, 22(2), 373-394.
- Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.. Platelets, 1-7.
- International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests.. J Thromb Thrombolysis.
- Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. Cochrane Database of Systematic Reviews, 2021(5).
- COMPLETE REVASCULARIZATION IN PATIENTS UNDERGOING A PHARMACOINVASIVE STRATEGY FOR STEMI. Journal of the American College of Cardiology, 77(18), 933.
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 42(14), 1289-1367.
- Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues.. Heart.
- Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection. JACC: Basic to Translational Science, 6(3), 219-221.
- A proteomics-based assessment of inflammation signatures in endotoxemia. Molecular & Cellular Proteomics, 20.
- Predictors, type, and impact of bleeding on the net clinical benefit of long‐term Ticagrelor in stable patients with prior myocardial infarction. Journal of the American Heart Association, 10(4).
- Contra. EUROPEAN HEART JOURNAL, 42(31), 2979-2985.
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.. Rev Esp Cardiol (Engl Ed), 74(6), 544.
- Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal. Acute Cardiovascular Care, 10(2), 153-163.
- Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 22(Supplement_M), M26-M34.
- Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus : a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 19(1). View this article in WRRO
- Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation, 142(Suppl_3).
- Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach. European Heart Journal, 41(Supplement_2).
- The Cardiac Complications of COVID-19; Many Publications, Multiple Uncertainties. Vascular Biology.
- The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 41(37), 3495-3497.
- The long journey of individualizing antiplatelet therapy after acute coronary syndromes. European Heart Journal, 41(37), 3546-3548.
- Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 76(11), 1277-1286.
- Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions.. EuroIntervention.
- Legumain in acute coronary syndromes: A substudy of the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American Heart Association, 9(17).
- Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology.
- Rationale and design of the LIBERATES trial : protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. Diabetes and Vascular Disease Research, 17(5).
- Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology, 76(2), 162-171.
- 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction. Heart, 106(Suppl 2), a41-a41.
- Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 13(7).
- Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos. Revista Española de Cardiología, 73(6), 495.e1-495.e61.
- Gut microbiota‐dependent trimethylamine N‐oxide and cardiovascular outcomes in patients with prior myocardial infarction: A nested case control study from the PEGASUS‐TIMI 54 trial. Journal of the American Heart Association, 9(10). View this article in WRRO
- Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial. Journal of the American Heart Association, 9(10).
- Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. International Journal of Molecular Sciences, 21(8). View this article in WRRO
- Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 382(16), 1568-1572.
- Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 120(04), 538-564.
- COMPLETE VERSUS CULPRIT-LESION-ONLY REVASCULARIZATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS. Journal of the American College of Cardiology, 75(11), 15-15.
- PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE. Journal of the American College of Cardiology, 75(11), 2194-2194.
- APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL. Journal of the American College of Cardiology, 75(11), 298-298.
- Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs. View this article in WRRO
- The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention : a prespecified sub-analysis of the GLOBAL LEADERS trial. Clinical Research in Cardiology. View this article in WRRO
- Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 75(3), 301-303.
- Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: A PLATO sub-study. Thrombosis and Haemostasis, 120(03), 412-422. View this article in WRRO
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology, 17(4), 242-257.
- 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 41(3), 407-477. View this article in WRRO
- Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 109(7), 930-943.
- Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?. EuroIntervention, 15(13), 1125-1129.
- 2019 ghidul SEC pentru diagnosticul si managementul sindroamelor coronariene cronice: Grupul de lucru pentru diagnosticul si managementul sindroamelor coronariene cronice al societatii europeene de cardiologie (SEC). Revista Romana de Cardiologie, 30(3), 467-548.
- Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. European Heart Journal, 41(3), 483-484.
- Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 6(4), 222-230.
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 41(17), 1625-1632.
- Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 120(01), 065-074.
- Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation, 141(9), 781-783.
- ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 293, 35-41.
- Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 74(22), 2713-2723.
- 2349: Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients. EUROPEAN HEART JOURNAL, 40(Suppl 1), 1355-1355. View this article in WRRO
- Complete revascularization with multivessel PCI for myocardial infarction. New England Journal of Medicine, 381(15), 1411-1421. View this article in WRRO
- P6411Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes. European Heart Journal, 40(Supplement_1).
- TCT-404 Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes: Insights From the Randomized GLOBAL LEADERS Trial. Journal of the American College of Cardiology, 74(13), B400-B400.
- Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 5(4), 200-206. View this article in WRRO
- Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 4(11), 1092-1092.
- C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(11), 2402-2410.
- Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets. View this article in WRRO
- Aspirin and Primary Prevention in Patients with Diabetes—A Critical Evaluation of Available Randomized Trials and Meta-Analyses. Thrombosis and Haemostasis, 119(10), 1573-1582.
- Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice. Thrombosis and Haemostasis, 119(10), 1590-1605.
- Antithrombotics. Journal of the American College of Cardiology, 74(5), 699-711.
- Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. American Heart Journal, 215, 157-166.
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 12(16), 1521-1537.
- Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?. JACC: Cardiovascular Interventions, 12(10), 993-994.
- Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal, 213, 57-65.
- Effect of Hypoglycemia on Inflammatory Responses and the Response to Low Dose Endotoxemia in Humans.. Journal of Clinical Endocrinology and Metabolism, 104(4), 1187-1199. View this article in WRRO
- Impact of diabetes Mellitus and Chronic Kidney Disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: Insights from the PLATO trial. Journal of the American Heart Association, 8(6). View this article in WRRO
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. New England Journal of Medicine. View this article in WRRO
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?. Thrombosis and Haemostasis. View this article in WRRO
- Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 115(10), 1512-1518.
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(2), 294-302.
- Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 19(2), 173-183.
- Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial. Catheterization and Cardiovascular Interventions, 93(7), E369-E377.
- 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Europace, 21(2), 192-193.
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
- Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes. Diabetes Care, 41(12), 2625-2633. View this article in WRRO
- Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Journal of the American Heart Association, 7(22). View this article in WRRO
- Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes. JAMA Cardiology, 3(12), 1160-1160.
- Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.. British Journal of Clinical Pharmacology. View this article in WRRO
- Abstract 16771: Patient Selection for Therapies to Prevent Major Adverse Limb Events. Circulation, 138(Suppl_1).
- Abstract 16658: Patient Selection for Long-Term Secondary Prevention With Ticagrelor: Insights From PEGASUS-TIMI 54. Circulation, 138(Suppl_1).
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- P823Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy. European Heart Journal, 39(suppl_1).
- P4404Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy. European Heart Journal, 39(suppl_1).
- Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 15(8), 480-496.
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Response by Angiolillo et al to Letter Regarding Article, “International Expert Consensus Document on Switching Platelet P2Y 12 Receptor Inhibiting Therapies”. Circulation, 137(21), 2310-2311.
- Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal, 202, 54-60.
- Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: A PLATO substudy. European Heart Journal, 39(13), 1078-1085. View this article in WRRO
- Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction. Blood Advances, 2(6), 715-730.
- Dual antiplatelet therapy in the ‘real world’. Heart, 104(19), 1555-1556.
- Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 39(19), 1672-1686f.
- Clot lysis time could identify heart attack patients most at risk of subsequent cardiovascular disease. BRITISH JOURNAL OF HOSPITAL MEDICINE, 79(3), 131-131.
- Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation, 137(7), 684-692.
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 71(5), 489-496.
- Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thrombosis and Haemostasis, 118(02), 427-429.
- Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. American Heart Journal, 196, 56-64.
- Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 39(3), e1-e33.
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 39(3), 213-260.
- Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Journal of the American Heart Association, 7(2). View this article in WRRO
- Reply. Journal of the American College of Cardiology, 71(1), 108-108.
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.. European Journal of Cardio-thoracic Surgery, 53(1), 34-78.
- Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS. Revista Española de Cardiología, 71(1), 42.e1-42.e58.
- The challenges of antithrombotic therapy in patients with left ventricular thrombosis. European Heart Journal, 39(3), 209-211.
- Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). EP Europace, 19(11), 1757-1758.
- International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies. Circulation, 136(20), 1955-1975.
- Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 70(14), 1760-1776.
- Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. International Journal of Cardiology, 244, 49-53.
- Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. Journal of the American College of Cardiology, 70(11), 1368-1375.
- Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 6(6), 500-510.
- The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease. JACC - Journal of the American College of Cardiology bts, 2(4), 398-414. View this article in WRRO
- Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. European Heart Journal: Acute Cardiovascular Care.
- P3670Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal, 38(suppl_1).
- 2864Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 38(suppl_1).
- Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 70(5), 527-538.
- Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 44(2), 145-153. View this article in WRRO
- Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.. Clin Cardiol.
- Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. European Heart Journal, 38(22), 1710-1716.
- Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention, 13(1), 69-77.
- Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes Following Treatment With Ticagrelor. The American Journal of Cardiology, 119(8), 1135-1140.
- Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 6(4), e005580-e005580. View this article in WRRO
- Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 186, 91-99.
- Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis, 117(5), 940-947.
- Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients. Platelets, 28(8), 767-773. View this article in WRRO
- Monitoring Antiplatelet Therapy.. Semin Thromb Hemost, 43(3), 311-319.
- Steen Elkjær Husted MD FESC 1950–2016. European Heart Journal, 38(7), 472-472.
- Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clinical Chemistry, 63(2), 573-584.
- Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction. Int. Journal of Clinical Pharmacology and Therapeutics, 55(05), 416-424.
- BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. Thrombosis and Haemostasis, 117(2), 295-302.
- Ticagrelor: Effects Beyond the P2Y12 Receptor.. Interv Cardiol Clin, 6(1), 49-55. View this article in WRRO
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
- Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
- The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) - a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial.. Trials, 17(1), 579-579. View this article in WRRO
- Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. The Journal of Clinical Pharmacology.
- Abstract 12851: Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation, 134(suppl_1).
- Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, ehw454-ehw454.
- 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Giornale Italiano di Cardiologia, 17(10), 831-872.
- Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation, 134(12), 861-871.
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
- Studies of the interaction of ticagrelor with the P2Y 13 receptor and with P2Y 13 -dependent pro-platelet formation by human megakaryocytes. Thrombosis and Haemostasis, 116(6), 1079-1088.
- Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. Int. Journal of Clinical Pharmacology and Therapeutics, 54(09), 666-674.
- Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. Vascular Pharmacology, 84, 25-27.
- Cangrelor for the management and prevention of arterial thrombosis. Expert Review of Cardiovascular Therapy, 14(9), 991-999. View this article in WRRO
- Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 1(4), 425-425.
- Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Heart Journal, 177, 1-8.
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 67(23), 2719-2728.
- Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54. Journal of the American College of Cardiology, 67(23), 2732-2740.
- P2Y₁₂ receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: The PRIVATE-ATLANTIC study. Thrombosis and Haemostasis, 116(2), 369-378.
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
- Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thrombosis and Haemostasis, 116(1), 96-102.
- Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart, 102(8), 617-625.
- Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Current Cardiology Reports, 18(5).
- Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H24 Analysis. JACC: Cardiovascular Interventions, 9(7), 646-656.
- Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 115(4), 685-711.
- Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Human Molecular Genetics, 25(7), 1447-1456.
- Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. Journal of the American College of Cardiology, 67(10), 1145-1154. View this article in WRRO
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Russian Journal of Cardiology, 131(3), 9-63.
- Association of MicroRNAs and YRNAs With Platelet FunctionNovelty and Significance. Circulation Research, 118(3), 420-432. View this article in WRRO
- CRT-200.62 The Impact of Ticagrelor on Platelet Reactivity in African Americans: Interim Results of the ACS Ethnicity Study. JACC: Cardiovascular Interventions, 9(4), S22-S22.
- Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation: Arrhythmia and Electrophysiology, 9(2).
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 37(3), 267-315.
- CardioPulse: 'Ten Commandments' of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS).. Eur Heart J, 37(3), 208.
- Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. International Journal of Cardiology, 202, 167-173.
- Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 37(14), 1133-1142.
- Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 37(16), 1325-1333.
- Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. European Heart Journal: Acute Cardiovascular Care, 5(1), 3-12.
- 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Española de Cardiología (English Edition), 68(12), 1125-1125.
- Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología, 68(12), 1125.e1-1125.e64.
- Platelet P2Y 12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(12), 2562-2570. View this article in WRRO
- Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial. Circulation, 132(suppl_3).
- Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy. Circulation, 132(suppl_3).
- Abstract 11594: Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Circulation, 132(suppl_3).
- Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. Circulation, 132(suppl_3).
- “Heart Team” decision making in elderly patients with symptomatic aortic valve stenosis who underwent AVR or TAVI – a look behind the curtain. Results of the prospective TAVI Calculation of Costs Trial (TCCT). EuroIntervention, 11(8), 793-798.
- Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention, 11(8), 737-745.
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: An analysis from the platelet inhibition and patient outcomes (PLATO) trial. Journal of the American Heart Association, 4(10). View this article in WRRO
- The role of platelets in inflammation. Thrombosis and Haemostasis, 114(09), 449-458.
- Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y
12 receptors in vitro. Platelets, 27(3), 191-195. View this article in WRRO - Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. Vascular Pharmacology, 71, 201-207. View this article in WRRO
- Effect of P2Y12 inhibitors on inflammation and immunity. Thrombosis and Haemostasis, 114(09), 490-497.
- The future of P2Y12receptor antagonists. Platelets, 26(5), 392-398.
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 372(19), 1791-1800.
- More transparency for a therapeutic window in platelet P2Y12inhibition?. European Heart Journal, 36(27), 1714-1717.
- Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 36(29), 1901-1912.
- Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period.. Platelets, 26(3), 271-273.
- Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex. The American Journal of Medicine, 128(8), 914.e11-914.e19.
- Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. American Heart Journal, 170(3), 465-470.
- NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes. Circulation: Cardiovascular Genetics, 8(3), 498-506.
- Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 169(6), 879-889.e7.
- Reply. Journal of the American College of Cardiology, 65(5), 516-518.
- Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?. Thrombosis and Haemostasis, 113(02), 221-230.
- How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?. Thrombosis and Haemostasis, 113(01), 37-52.
- 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Kardiologia Polska, 1207-1294.
- How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?. Thrombosis and Haemostasis, 113(01), 37-52.
- Expert position paper on air pollution and cardiovascular disease. European Heart Journal, 36(2), 83-93.
- Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. European Heart Journal: Acute Cardiovascular Care, 4(6), 555-560.
- Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 101(2), 119-125.
- Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study. European Heart Journal: Acute Cardiovascular Care, 4(3), 254-262.
- PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets, 26(3), 236-242.
- Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 22(6), 734-742.
- Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(24), 2337-2339.
- Prehospital ticagrelor in ST-segment elevation myocardial infarction.. N Engl J Med, 371(24), 2338-2339.
- Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal, 35(45), 3155-3179.
- Abstract 20470: Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes. Circulation, 130(suppl_2).
- Abstract 20657: Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function. Circulation, 130(suppl_2).
- Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 64(12), 1270-1280.
- Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 371(11), 1016-1027.
- Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal, 35(31), 2083-2093.
- Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgraduate Medical Journal, 90(1067), 520-528.
- No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.. Int J Cardiol, 176(1), 300-302.
- Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.. Heart, 100(22), 1762-1769.
- Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European Heart Journal, 35(23), 1510-1514.
- The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.. Eur Heart J, 35(23), 1541-1550.
- 215 Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia. Heart, 100(Suppl 3), A117.3-A118.
- Beware the normal angiogram.. Clin Med (Lond), 14(3), 323-324.
- Response to Letter Regarding Article, "Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial". CIRCULATION, 129(19), E494-E495.
- Utilisation of novel anti-platelet agents: Evidence, guidelines and proven patients' value. Thrombosis and Haemostasis, 112(1), 12-14.
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. THROMBOSIS AND HAEMOSTASIS, 111(5), 781-782.
- Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. American Heart Journal, 168(4), 530-536.
- Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).. J Am Coll Cardiol, 63(11), 1048-1057.
- Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.. J Am Coll Cardiol, 63(15), 1493-1499.
- Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.. Cardiovasc Res, 102(3), 429-435.
- Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.. Circulation, 129(3), 293-303.
- Can we improve the efficacy of low-dose aspirin?. Thrombosis and Haemostasis, 112(12), 1077-1078.
- Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal.
- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes: The TRACER pharmacodynamic substudy. Thrombosis and Haemostasis, 111(5), 883-891.
- Genetics of response to antiplatelet therapy.. Prog Mol Biol Transl Sci, 124, 123-153.
- Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 35(4).
- Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal.
- Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).. Am J Cardiol, 113(6), 936-944.
- Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes.. J Cardiovasc Transl Res, 7(1), 19-28.
- Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.. Platelets, 25(7), 517-525.
- Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.. Platelets, 25(6), 416-422.
- Abstract 18427: Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease. Circulation, 128(suppl_22).
- Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial.. J Am Coll Cardiol..
- Response variability to P2Y
12 receptor inhibitors: Expectations and reality. JACC: Cardiovascular Interventions, 6(11), 1111-1128. - Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with or without In-Hospital Revascularization: A Substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial.. Circulation.
- Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.. Circulation, 128(10), 1055-1065.
- Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: Results from the PLATelet inhibition and patient outcomes (PLATO) study. Clinical Chemistry, 59(9), 1369-1375.
- Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose. European Heart Journal, 34(suppl 1), P4881-P4881.
- GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study. European Heart Journal, 34(suppl 1), P4048-P4048.
- Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial. European Heart Journal, 34(suppl 1), P4901-P4901.
- Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. European Heart Journal, 34(suppl 1), 4536-4536.
- Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. European Heart Journal, 34(suppl 1), 4533-4533.
- PAR-1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 444-444.
- Diabetes modulates the fibrinolytic properties of aspirin without altering the platelet inhibitory actions: a possible mechanism for aspirin treatment failure. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 760-760.
- Zebrafish as a model to investigate the effect of P2Y12 knockdown on leukocyte migration. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 450-450.
- The role of vessel wall P2Y12 in early atherogenesis is not blocked by ticagrelor or clopidogrel. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 156-156.
- Evolving pattern of platelet P2Y12 inhibition during maintenance therapy in acute coronary syndrome patients. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 11, 494-494.
- Angiographic outcomes in the PLATO trial (Platelet inhibition and patient outcomes). JACC: Cardiovascular Interventions, 6(7), 671-683.
- Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. EUROPEAN HEART JOURNAL, 34(23), 1708-+.
- Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.. EuroIntervention, 9(1), 62-69.
- Ticagrelor in patients with acute coronary syndromes and stroke: Interpretation of subgroups in clinical trials. Stroke, 44(5), 1477-1479.
- Antiplatelet therapy: Cangrelor succeeds, at last, in PCI. Nature Reviews Cardiology, 10(6), 302-304.
- Platelet function testing and prediction of procedural bleeding risk.. Thromb Haemost, 109(5).
- Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation, 127(6), 673-680.
- Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.. Thromb Haemost, 109(3), 550-555.
- ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa de Cardiologia (English Edition), 32(1), 83-84.
- ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista Portuguesa de Cardiologia (English Edition), 32(1), 81-82.
- Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment: a substudy from the prospective randomized PLATelet inhibit.. Pharmacotherapy(33), E189-E189.
- Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome. Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial, International Journal of Cardiology,. International Journal of Cardiology.
- Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes. PLATELETS, 24(8), 643-648.
- Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thrombosis and Haemostasis, 110(3), 609-615.
- Quantitative ST-depression in acute coronary syndromes: The plato electrocardiographic substudy. American Journal of Medicine, 126(8).
- Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes - Results from the PLATO Trial. Value in Health, 16(4), 574-580.
- An International Perspective of Current Patterns of Antiplatelet Drug Use in Acute Coronary Syndrome Patients. Results from the EPICOR Study. CIRCULATION, 126(21).
- Third universal definition of myocardial infarction. Nature Reviews Cardiology, 9(11), 620-633.
- Platelet Function Testing in Atherothrombotic Disease. CURRENT PHARMACEUTICAL DESIGN, 18(33), 5379-5391.
- 'Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial' [Eur Heart J 2011; 32:2933-2944, doi:10.1093/eurheartj/ehr422. R.C. Becker, J.P. Bassand, A. Budaj, D.M. Wojdyla, S.K. James, J.H. Cornel, J. French, C. Held, J. Horrow, S. Husted, J. Lopez-Sendon, R. Lassila, K.W. Mahaffey, R.F. Storey, R.A. Harrington, L. Wallentin. European Heart Journal, 33(21), 2750-2750.
- Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 60(16), 1581-1598.
- Third Universal Definition of Myocardial Infarction. Circulation, 126(16), 2020-2035.
- Third universal definition of myocardial infarction. European Heart Journal, 33(20), 2551-2567.
- Response to Letter Regarding Article, "Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO". CIRCULATION, 126(11), E171-E172.
- Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 5(5), 680-688.
- Development and clinical use of prasugrel and ticagrelor.. Curr Pharm Des, 18(33), 5240-5260.
- ESC guidelines for the treatment of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Giornale Italiano di Cardiologia, 13(3), 171-228.
- ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Revista Española de Cardiología (English Edition), 65(2), 173-173.
- Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología, 65(2), 173.e1-173.e55.
- Contemporary management of ST-segment elevation myocardial infarction.. Hosp Pract (1995), 40(1), 224-231.
- Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients-Results from the PLATelet inhibition and patient Outcomes (PLATO) study. American Heart Journal.
- Factors Contributing to the Lower Mortality With Ticagrelor Compared With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology.
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation, 125(23), 2914-2921.
- Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: Insights from the PLATO trial. CMAJ, 184(10), 1135-1142.
- Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal.
- Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: Results from the ONSET-OFFSET and RESPOND studies. Clinical Pharmacokinetics, 51(6), 397-409.
- Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from the platelet inhibition and patient outcomes trial. Circulation, 125(8), 978-986.
- Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. New England Journal of Medicine, 366(1), 20-33.
- ST-elevation acute coronary syndromes in the platelet inhibition and patient outcomes (PLATO) trial: Insights from the ECG substudy. Circulation, 125(3), 514-521.
- Republished education in heart: New P2Y₁₂ inhibitors.. Postgrad Med J, 88(1035), 49-54.
- Cystatin C and Estimated Glomerular Filtration Rate as Predictors for Adverse Outcome in Patients with ST-Elevation and Non-ST-Elevation Acute Coronary Syndromes: Results from the Platelet Inhibition and Patient Outcomes Study. CLINICAL CHEMISTRY, 58(1), 190-199.
- Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention.. Curr Treat Options Cardiovasc Med, 14(1), 24-38.
- Wytyczne dotycza̧ce diagnostyki i leczenia ostrych zespołów wieńcowych bez przetrwałego uniesienia odcinka ST. Kardiologia Polska, 69(SUPPL. 5).
- ST Elevation Acute Coronary Syndromes in PLATO. Circulation, 1-1.
- Wytyczne ESC/EAS dotycza̧ce postêpowania w dyslipidemiach. Kardiologia Polska, 69(SUPPL. 4).
- ESC/EAS Guidelines for the management of dyslipidaemias. Revista Española de Cardiología (English Edition), 64(12), 1168-1168.
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32(23), 2999-3054.
- Israrci ST-segment yükselmesi belirtileri göstermeyen hastalarda Akut KoronerSendromlarin (AKS) tedavi kilavuzlari. Turk Kardiyoloji Dernegi Arsivi, 39(SUPP -3), 73-128.
- ESC/EAS Kilavuzlari: Dislipidemilerin tedavisi. Turk Kardiyoloji Dernegi Arsivi, 39(SUPP -3), 5-72.
- Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología, 64(12), 1168.e1-1168.e60.
- Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial. CIRCULATION, 124(21).
- Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial. CIRCULATION, 124(21).
- Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).. Am J Cardiol, 108(11), 1542-1546.
- Ticagrelor Compared with Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 124(5), 660-660.
- Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 124(5), 544-U78.
- Serial renal function assessment with cystatin c in patients with acute coronary syndrome randomized to ticagrelor or clopidogrel. EUROPEAN HEART JOURNAL, 32, 417-417.
- Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention -an analysis from the prospective randomized PLATO trial. EUROPEAN HEART JOURNAL, 32, 415-416.
- New P2Y(12) inhibitors. HEART, 97(15), 1262-1267.
- Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.. Eur Heart J, 32(23), 2945-2953.
- ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 217, 1-44.
- ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 217(1), 3-46.
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 32(14), 1769-1818.
- Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.. J Thromb Haemost, 9(9), 1730-1737.
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BRIT MED J, 342. View this article in WRRO
- Update on lipids, inflammation and atherothrombosis. THROMB HAEMOSTASIS, 105, S34-S42.
- The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial Results of the Continuous Electrocardiographic Assessment Substudy. J AM COLL CARDIOL, 57(19), 1908-1916.
- Education in atherothrombosis.. Thromb Haemost, 105 Suppl 1, S1-S2.
- Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.. Thromb Haemost, 105 Suppl 1, S75-S81.
- Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery.. J Am Coll Cardiol, 57(9), 1078-1080.
- Ticagrelor: from concept to clinical evaluation.. Biomark Med, 5(1), 53-62.
- Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine, 1-15.
- Bleeding complications with the P
2 Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. European Heart Journal, 32(23), 2933-2944. - Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal, 32(23), 2922-2932.
- Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the platelet inhibition and patient outcomes [PLATO] pulmonary function substudy). American Journal of Cardiology, 108(11), 1542-1546.
- The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal.
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.. J Am Coll Cardiol, 57(6), 672-684.
- Sustained P2Y12 Receptor Inhibition is Required to Effectively Inhibit Neointima Formation in a Murine Vascular Injury Model. CIRCULATION, 122(21).
- First Analysis of Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor versus Clopidogrel Treated Patients: Results from the ONSET/OFFSET and RESPOND Studies. CIRCULATION, 122(21).
- Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy (vol 56, pg 1456, 2010). J AM COLL CARDIOL, 56(22), 1895-1895.
- First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.. Circ Cardiovasc Genet, 3(6), 556-566.
- Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.. Arterioscler Thromb Vasc Biol, 30(12), 2385-2391.
- Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.. Circulation, 122(21), 2131-2141.
- POS10 Variability in patient response to clopidogrel and effects on outcome from carotid stenting.. J Neurol Neurosurg Psychiatry, 81(11), e69-e70.
- What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?. Diab Vasc Dis Res, 7(4), 249-250.
- Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, 122(11), 1056-1067.
- Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.. J Am Coll Cardiol, 56(18), 1456-1462.
- Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.. Eur Heart J, 31(24), 3006-3016.
- Current strategies in antiplatelet therapy - Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. PHARMACOL THERAPEUT, 127(2), 95-107.
- Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.. J Am Coll Cardiol, 56(3), 185-193.
- Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.. J Thromb Haemost, 8(8), 1820-1827.
- Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function.. Thromb Haemost, 103(6), 1210-1217.
- Stabilizing Role of Platelet P2Y(12) Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques. PLOS ONE, 5(4). View this article in WRRO
- Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel. CLIN CARDIOL, 33(4), 206-212.
- Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies The RESPOND Study. CIRCULATION, 121(10), 1188-1199.
- TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY. Journal of the American College of Cardiology, 55(10), A108.E1007-A108.E1007.
- THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL. Journal of the American College of Cardiology, 55(10), A108.E1006-A108.E1006.
- Comparison of ticagrelor with clopidogrel in patients with planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. LANCET, 375(9711), 283-293.
- Erratum to Current strategies in antiplatelet therapy - Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? [Pharmacol. Ther., 127(2), (2010), 95-107]. Pharmacology and Therapeutics, 128(2), 385.
- Antiplatelet therapy and vascular disease: An update. Therapeutic Advances in Cardiovascular Disease, 4(4), 249-275.
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet.
- Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.. Circulation, 120(25), 2577-2585.
- The right oral antithrombotics in acute coronary syndromes. LANCET, 374(9706), 1947-1948.
- Antiplatelet therapy for acute coronary syndrome treated with percutaneous coronary intervention: New Developments Conclusions. EUR HEART J SUPPL, 11(G), G25-G26.
- Antiplatelet therapy for acute coronary syndrome treated with percutaneous coronary intervention: New Developments Introduction. EUR HEART J SUPPL, 11(G), G2-G3.
- Abstract 5768: The Effect of Ticagrelor on Cardiopulmonary Function in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
- Abstract 5762: A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
- Abstract 5495: More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. Circulation, 120(suppl_18).
- Abstract 5494: Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease. Circulation, 120(suppl_18).
- Abstract 4947: Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. Circulation, 120(suppl_18).
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. NEW ENGL J MED, 361(11), 1045-1057.
- Cangrelor inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor. EUROPEAN HEART JOURNAL, 30, 193-193.
- The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale. AM HEART J, 158(3), 327-U5.
- Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.. Platelets, 20(5), 341-348.
- Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. AM HEART J, 157(4), 599-605.
- Bleeding risk with AZD6140, a reversible P2Y(12) receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. INT J CLIN PRACT, 63(4), 667-670.
- Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease, 1-14.
- Clopidogrel in acute coronary syndrome: to genotype or not?. Lancet, 373(9660), 276-278.
- Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.. Circulation, 119(1), 116-122.
- Final aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation response. EUROPEAN HEART JOURNAL, 29, 405-405.
- Platelet function assays that assess response to P2Y12 antagonists vary widely in their sensitivities to low levels of P2Y12 receptor blockade. EUROPEAN HEART JOURNAL, 29, 835-835.
- Aspirin resistance and diabetes mellitus. DIABETOLOGIA, 51(3), 385-390.
- The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.. Platelets, 19(2), 125-133.
- Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. PLATELETS, 19(4), 239-251.
- ARL66096, 1-2.
- AR-C69931MX, 1-4.
- ARL67085, 1-3.
- Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial (vol 50, pg 1844, 2007). J AM COLL CARDIOL, 50(22), 2196-2196.
- Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial. J AM COLL CARDIOL, 50(19), 1844-1851.
- Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.. J Am Coll Cardiol, 50(19), 1852-1856.
- Abciximab can potentiate platelet alpha-granule release and this effect is prevented by the P2Y12 antagonist cangrelor. EUROPEAN HEART JOURNAL, 28, 665-666.
- INHIBITION OF THROMBOSIS BY AZD6140 VIA SELECTIVE BLOCKADE OF THE P2Y12 RECEPTOR IN A MURINE LASER-INJURY MODEL. Journal of Thrombosis and Haemostasis, 5.
- Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.. Thromb Haemost, 95(6), 997-1002.
- Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.. Platelets, 17(4), 250-258.
- Biology and pharmacology of the platelet P2Y12 receptor.. Curr Pharm Des, 12(10), 1255-1259.
- Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.. Platelets, 16(7), 398-407.
- Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor.. Thromb Haemost, 94(4), 831-838.
- PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.. Platelets, 16(6), 340-345.
- Comparison of Two Strategies for the Management of Antiplatelet Therapy During Urgent Surgery. The Annals of Thoracic Surgery, 80(1), 149-152.
- Inhibitory effects of P2Y(12) receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. PLATELETS, 16(2), 73-80.
- Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.. Thromb Res, 115(4), 301-307.
- Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.. Platelets, 15(8), 465-474.
- Clopidogrel resistance.. Catheter Cardiovasc Interv, 63(3), 397-398.
- Anticoagulants, antiplatelets and thrombolytics. British Journal of Clinical Pharmacology, 58(4), 442-442.
- Antiplatelet therapy in cardiovascular disease. POSTGRAD MED J, 80(941), 155-164.
- Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.. Platelets, 13(7), 407-413.
- Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.. Thromb Haemost, 88(3), 488-494.
- Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood.. Platelets, 12(7), 443-447.
- The P2Y12 receptor as a therapeutic target in cardiovascular disease.. Platelets, 12(4), 197-209.
- Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.. Thromb Haemost, 85(3), 401-407.
- The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.. Br J Haematol, 110(4), 925-934.
- P2T receptor activation by released ADP dramatically amplifies platelet procoagulant activity and calcium mobilisation induced by thrombin receptor (PAR1) activation. EUR HEART J, 21, 66-66.
- In vitro evidence supporting direct platelet P2T receptor antagonism as an alternative strategy to glycoprotein IIB/IIIA receptor antagonism. Heart, 83(SUPPL. 1).
- O4 Heparins sensitize platelets to responses mediated via both the P27 and the P2Y1 receptor pathways. Blood Coagulation & Fibrinolysis, 10(8), 531-531.
- Heparins sensitize platelets to responses mediated via both the P-2T and the P2Y(1) receptor pathways. CIRCULATION, 100(18), 680-680.
- First clinical study of the novel platelet ADP receptor (P-2 gamma) antagonist AR-C69931MX, assessing safety, tolerability and activity in patients with acute coronary syndromes. CIRCULATION, 100(18), 710-710.
- A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.. Thromb Haemost, 82(4), 1307-1311.
- Laboratory investigation of platelet function.. Clin Lab Haematol, 21(5), 317-329.
- Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries. BRIT J PHARMACOL, 128, U31-U31.
- Does occupation of the P-2t, receptor on platelets by ADP lead to a reduced rate of Ca2+ re-uptake following Ca2+liberation via the P2Y(1) receptor, and is this mediated by a fall in basal camp?. THROMB HAEMOSTASIS, 355-356.
- Contribution of P-2t, and P2Y(1), receptors to ADP-induced platelet microaggregation in human whole blood. THROMB HAEMOSTASIS, 260-260.
- The effects of a P-2T antagonist on platelet aggregation, platelet activation and platelet-leukocyte conjugate formation in vitro and following administration to patients with unstable angina. THROMB HAEMOSTASIS, 11-11.
- Influence of the ADP antagonists AR-C67085 and A2P5P on ADP-induced responses of platelets and isolated arteries. THROMB HAEMOSTASIS, 166-167.
- Administration of a GPIIb/IIIa antagonist to patients with unstable angina: Effects on platelet aggregation and platelet-leucocyte conjugate formation. THROMB HAEMOSTASIS, 357-358.
- The central role of the P-2T receptor in amplification of platelet aggregation and secretion. THROMB HAEMOSTASIS, 420-420.
- Monitoring the effects of glycoprotein IIb/IIIa antagonists using a whole blood assay of platelet microaggregation: Comparison with other aggregation methodologies. Hamostaseologie, 19(3), 115-118.
- In vitro effects of the novel platelet adenosine diphosphate receptor (P-2T) antagonist AR-C69931MX and aspirin on platelet aggregation in human whole blood: a potential new therapy for arterial thrombosis.. CIRCULATION, 98(17), 560-560.
- Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.. Circulation, 98(16), 1616-1621.
- Electrocardiogram interpretation - Response. JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON, 32(1), 85-85.
- Electrocardiogram interpretation as a basis for thrombolysis.. J R Coll Physicians Lond, 31(5), 536-540.
- Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding. European Heart Journal.
- Invasive Treatment Strategy for Older Patients with Myocardial Infarction. New England Journal of Medicine.
- Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 1-7.
- Clinical decision aids and computed tomography coronary angiography in patients with suspected acute coronary syndrome. Emergency Medicine Journal.
- Modelled impact of virtual fractional flow reserve in patients undergoing coronary angiography (VIRTU-4). Heart.
- Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes. Interventional Cardiology: Reviews, Research, Resources, 19.
- Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry. Journal of Thrombosis and Thrombolysis.
- Temporal biomarker concentration patterns during the early course of acute coronary syndrome. Clinical Chemistry and Laboratory Medicine (CCLM), 0(0).
- Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis. Cochrane Database of Systematic Reviews, 2024(1).
- Antithrombotic Therapy in Patients with Acute Coronary Syndrome: Similarities and Differences between a European Expert Consensus Document and the 2023 European Society of Cardiology Guidelines. European Heart Journal: Acute Cardiovascular Care.
- Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure. European Heart Journal - Cardiovascular Pharmacotherapy.
- Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence.
- Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction. Expert Opinion on Drug Metabolism & Toxicology, 1-12.
- THE ROLE OF PLATELET P2Y12 IN INFLAMMATION. British Journal of Pharmacology.
- Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. European Heart Journal - Cardiovascular Pharmacotherapy.
- Conservative versus Invasive Strategy in Elderly Patients with Non-ST-Elevation Myocardial Infarction: Insights from the International POPular Age Registry. Journal of Clinical Medicine, 12(17), 5450-5450.
- De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nature Reviews Cardiology.
- Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. European Heart Journal.
- Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding. European Heart Journal.
- Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease. Two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC) and European Association of Preventive Cardiology (EAPC). European Heart Journal - Cardiovascular Pharmacotherapy.
- Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial. Journal of the American Heart Association.
- Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care.
- Acute, periprocedural and longterm antithrombotic therapy in older adults. European Heart Journal.
- Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. European Heart Journal.
- Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction. JAMA Cardiology.
- Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions. Thrombosis and Haemostasis.
- Resumption of Antiplatelet Therapy after Major Bleeding. Thrombosis and Haemostasis.
- Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. European Heart Journal. Acute Cardiovascular Care.
- Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial. BMJ, o438-o438.
- Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research.
- Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA , a multi‐country observational study. Clinical Cardiology.
- Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial. Circulation: Cardiovascular Interventions.
- Antithrombotic therapy in diabetes: which, when, and for how long?. European Heart Journal.
- Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial. Circulation.
- Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. Circulation: Genomic and Precision Medicine.
- Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. Platelets, 1-6.
- Meta‐analysis of echocardiographic quantification of left ventricular filling pressure. ESC Heart Failure.
- Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Circulation.
- Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal. Acute Cardiovascular Care.
- Antithrombotic therapy for patients with chronic coronary syndromes. Heart.
- Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. European Heart Journal - Cardiovascular Pharmacotherapy.
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology.
- Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. Cardiovascular Drugs and Therapy.
- Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction. JAMA Cardiology.
- Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, haematol.2019.239558-haematol.2019.239558.
- Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal - Cardiovascular Pharmacotherapy.
- Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1-8.
- Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 1-7.
- Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial. European Heart Journal: Acute Cardiovascular Care, 204887261984633-204887261984633.
- Fourth universal definition of myocardial infarction (2018). Kardiologia Polska, 76(10), 1383-1415.
- Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
- Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, ehv482-ehv482.
- Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal, ehv304-ehv304.
- Third Universal Definition of Myocardial Infarction. Global Heart, 7(4), 275-275.
- Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
- New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 9(7), 2059-2059.
- Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. European Heart Journal.
- Interleukin‐18 in patients with acute coronary syndromes. Clinical Cardiology. View this article in WRRO
- Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes : insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis, 48(4), 563-569. View this article in WRRO
Chapters
- Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes In De Caterina R, Moliterno DJ & Kristensen SD (Ed.), The ESC Textbook of Thrombosis (pp. 179-C16P154). Oxford University PressOxford
- The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it?, Dual Antiplatelet Therapy for Coronary and Peripheral Arterial Disease (pp. 193-199). Elsevier
- Acute coronary syndromes: Thrombotic Response
- Platelets in Acute Coronary Syndromes, Platelets in Thrombotic and Non-Thrombotic Disorders (pp. 1015-1028). Springer International Publishing
- Prasugrel In Editors-in-Chief: S.J. Enna & David B. Bylund (Ed.), xPharm: The Comprehensive Pharmacology Reference (pp. 1-4). New York: Elsevier.
- MRS 2395 In Editors-in-Chief: S.J. Enna & David B. Bylund (Ed.), xPharm: The Comprehensive Pharmacology Reference (pp. 1-2). New York: Elsevier.
Conference proceedings papers
- S89 Prevalence of microspirometry-defined chronic obstructive pulmonary disease in two European cohorts of patients with significant smoking history hospitalised for acute myocardial infarction. ‘Total eclipse of the heart’ – COPD and cardiovascular disease
- 71 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Acute coronary syndromes & Interventional Cardiology
- First Report of the International Safe and Timely Antithrombotic Removal (STAR) Registry. SWISS MEDICAL WEEKLY, Vol. 153 (pp 109S-109S)
- Effects of Complete Revascularization in Relation to Left Ventricular Function in Patients With STEMI and Multivessel Disease: Data from the COMPLETE Randomized trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 82(17) (pp B250-B251)
- DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes. CIRCULATION, Vol. 148(25) (pp E283-E284)
- Left Anterior Descending Non-culprit Lesion Location And Clinical Outcomes In Patients With St-segment Elevation Myocardial Infarction And Multivessel Disease: Results From The Complete Trial. CIRCULATION, Vol. 148(25) (pp E298-E298)
- 171 Prevalence of a nice-defined indication for inclisiran in a real-world trans-pandemic acute coronary syndrome cohort. Stable IHD/Prevention/Hypertension/Lipids
- Effects of Complete Revascularization According to Age in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel: Insights From the COMPLETE Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 80(12) (pp B15-B15)
- Complete Revascularization Versus Culprit Lesion-Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 80(12) (pp B15-B15)
- Treatment and prognosis of elderly patients with non-ST-elevation myocardial infarction. EUROPEAN HEART JOURNAL, Vol. 43 (pp 2541-2541)
- Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. EUROPEAN HEART JOURNAL, Vol. 42 (pp 1491-1491)
- Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 78(19) (pp B82-B83)
- The Biomarker-Based ABC-ACS (Age, Biomarkers, Clinical History) Score Can Predict Major Bleeding Better Than Other Contemporary Scores in Patients on Dual Antiplatelet Therapy After Coronary Revascularization: Results of a Large Derivation and Validation Study. CIRCULATION, Vol. 144
- Antithrombotic Strategies According to Age in Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the Augustus Trial. CIRCULATION, Vol. 144
- Rationale, design and feasibility of conducting a real-world study of outcomes in patients with a history of MI receiving extended DAPT with ticagrelor 60 mg. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 29 (pp 129-129)
- Rapid Assessment of Potential Ischaemic Heart Disease With Ctca: The Rapid-ctca Trial. A Randomised Trial of Ctcain the Evaluation, Intervention and Outcome Ofadults With Suspected or Confirmed Acute Coronary Syndrome Presenting to the Emergency Department. CIRCULATION, Vol. 142(24) (pp E471-E472)
- A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease. CIRCULATION, Vol. 142
- LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Journal of the American College of Cardiology, Vol. 73(9) (pp 196-196)
- Non-Culprit Lesion Plaque Morphology in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography (OCT) Substudy. CIRCULATION, Vol. 140(25) (pp E982-E983)
- Prolonged Enoxaparin Infusion in Patients Undergoing Primary Percutaneous Coronary Intervention Compared to Standard-of-care: A Single-centre Clinical Trial. CIRCULATION, Vol. 140
- Novel CYP2C19 Genetic Variants Associated With Stent Thrombosis - A Next Generation Sequencing Study. CIRCULATION, Vol. 140
- Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes. EUROPEAN HEART JOURNAL, Vol. 40 (pp 4011-4011)
- Acute hypoglycaemia results in increased activation of responses to an inflammatory challenge induced 48 hours later in human subjects. DIABETOLOGIA, Vol. 61 (pp S446-S446)
- Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy. EUROPEAN HEART JOURNAL, Vol. 39 (pp 882-883)
- Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 39 (pp 145-146)
- Adverse Fibrin Clot Properties Are Associated With Worse Outcome Following Acute Coronary Syndrome: A PLATO Substudy. CIRCULATION, Vol. 136 View this article in WRRO
- INHIBITORY MECHANISMS OF VERY LOW DOSE RIVAROXABAN IN NON-ST-ELEVATION MYOCARDIAL INFARCTION. Journal of the American College of Cardiology, Vol. 71(11) (pp A1398-A1398)
- ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR. Journal of the American College of Cardiology, Vol. 71(11) (pp A30-A30)
- Patient Selection for Therapies to Prevent Major Adverse Limb Events. CIRCULATION, Vol. 138
- Long-Term Secondary Prevention With Ticagrelor for Prior Myocardial Infarction in Patients With No Coronary Stenting: A Sub-Analysis From PEGASUS TIMI 54. CIRCULATION, Vol. 138
- High-Sensitivity Cardiac Troponin at Any Detectable Concentration Identifies Higher Risk of Major Cardiovascular Events in Patients With Stable Ischemic Heart Disease. CIRCULATION, Vol. 138
- Caffeine and Dyspnea With Ticagrelor: A Sub-Analysis From PEGASUS TIMI-54 Trial. CIRCULATION, Vol. 138
- Hypoglycaemia increases platelet reactivity and promotes formation of proatherogenic platelet-leucocyte aggregates. DIABETOLOGIA, Vol. 60 (pp S532-S532)
- Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. EUROPEAN HEART JOURNAL, Vol. 38 (pp 612-612)
- Effect of Hypoglycemia on Platelet Reactivity and Platelet-Leukocyte Kinetics. DIABETES, Vol. 66 (pp A41-A41)
- 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, Vol. 103(Suppl 5) (pp A53.2-A54)
- COMPARISON OF P2Y12 INHIBITORS FOR MORTALITY AND STENT THROMBOSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES: SINGLE CENTRE STUDY OF 10,793 CONSECUTIVE ‘REAL-WORLD’ PATIENTS. Journal of the American College of Cardiology, Vol. 69(11) (pp 1014-1014)
- Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, Vol. 134
- Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial. CIRCULATION, Vol. 134
- Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: the ATLANTIC ST-segment resolution substudy. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1173-1173)
- Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1282-1283)
- Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y12 receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 37 (pp 1224-1224)
- Platelet P2Y12 inhibitors enhance expansion of the intermediate monocyte population following systemic inflammation in humans. EUROPEAN HEART JOURNAL, Vol. 37 (pp 904-904)
- Potential role of ticagrelor in preventing venous and cardiac thrombosis: insights from PEGASUS-TIMI 54. EUROPEAN HEART JOURNAL, Vol. 37 (pp 636-637)
- 27 Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times. Heart, Vol. 102(Suppl 6) (pp A18-A18)
- SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 556-556)
- PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL. Journal of the American College of Cardiology, Vol. 67(13) (pp 493-493)
- EFFICACY AND SAFETY OF TICAGRELOR AS LONG-TERM SECONDARY PREVENTION IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION AND PERIPHERAL ARTERY DISEASE. Journal of the American College of Cardiology, Vol. 67(13) (pp 2266-2266)
- EFFICACY AND SAFETY OF TICAGRELOR FOR LONG-TERM SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH PRIOR MI AND MULTIVESSEL CORONARY DISEASE: INSIGHTS FROM THE PEGASUS-TIMI 54 TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 2146-2146)
- REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL. Journal of the American College of Cardiology, Vol. 67(13) (pp 2111-2111)
- Long-Term Tolerability of Ticagrelor in the PEGASUS-TIMI 54 Trial. CIRCULATION, Vol. 132(23) (pp 2272-2272)
- Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial. CIRCULATION, Vol. 132
- Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. CIRCULATION, Vol. 132
- GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy. CIRCULATION, Vol. 132
- Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. CIRCULATION, Vol. 132
- TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54. Journal of the American College of Cardiology, Vol. 66(15) (pp B36-B36)
- Efficacy and Safety of Ticagrelor for Long-Term Secondary Prevention of Atherothrombotic Events in Relation to Renal Function: Insights from the PEGASUS-TIMI 54 trial. EUROPEAN HEART JOURNAL, Vol. 36 (pp 520-520)
- Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC study. EUROPEAN HEART JOURNAL, Vol. 36 (pp 68-68)
- Balancing the risk of ischaemic and bleeding events in ACS. EUROPEAN HEART JOURNAL, Vol. 36 (pp 860-861)
- The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: insights from the PEGASUS-TIMI 54 trial. EUROPEAN HEART JOURNAL, Vol. 36 (pp 549-549)
- Associations of plasma microRNAs with platelet proteins and platelet function. EUROPEAN HEART JOURNAL, Vol. 36 (pp 230-230)
- Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction: the PEGASUS-TIMI 54 platelet function substudy. EUROPEAN HEART JOURNAL, Vol. 36 (pp 549-549)
- 203 Ticagrelor and Clopidogrel Attenuate the Prothrombotic State induced by Bacterial Endotoxaemia. Heart, Vol. 101(Suppl 4) (pp A112.1-A112)
- IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A15-A15)
- ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE (ALCAM) AND OUTCOMES IN ACUTE CORONARY SYNDROMES: A PLATO BIOMARKER SUBSTUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A231-A231)
- P2Y12 RECEPTOR INHIBITION ACCORDING TO PREHOSPITAL ADMINISTRATION OF TICAGRELOR IN PRIMARY PCI FOR ST ELEVATION MYOCARDIAL INFARCTION: THE PRIVATE-ATLANTIC STUDY. Journal of the American College of Cardiology, Vol. 65(10) (pp A221-A221)
- TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN ANALYSIS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 65(10) (pp A114-A114)
- TICAGRELOR INHIBITS CHANGES IN FIBRIN CLOT STRUCTURE INDUCED BY BACTERIAL ENDOTOXEMIA. Journal of the American College of Cardiology, Vol. 65(10) (pp A12-A12)
- TICAGRELOR POTENTIATES NEUTROPHIL PHAGOCYTOSIS VIA INHIBITION OF ADENOSINE REUPTAKE BY ERYTHROCYTES. Journal of the American College of Cardiology, Vol. 65(10) (pp A259-A259)
- Plasma microRNA levels in patients with acute coronary syndrome are associated with platelet function. Atherosclerosis, Vol. 237(2) (pp e5-e5)
- Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes. CIRCULATION, Vol. 130
- Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function. CIRCULATION, Vol. 130
- Secreted wingless (Wnt) antagonists and risk prediction in acute coronary syndrome (ACS) a PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 35 (pp 318-318)
- ApoA1 is independently associated with recurrent ischemic events and death in acute coronary syndrome patients. EUROPEAN HEART JOURNAL, Vol. 35 (pp 482-482)
- Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy. EUROPEAN HEART JOURNAL, Vol. 35 (pp 486-486)
- Ticagrelor inhibits release of pro-inflammatory cytokines TNF and IL-6 during human endotoxaemia. European Heart Journal, Vol. 35(Supp1) (pp 1170-1170), 30 August 2014 - 3 September 2014.
- Ticagrelor and dipyridamole potentiate adenosine-induced stimulation of neutrophil chemotaxis in the presence of erythrocytes. EUROPEAN HEART JOURNAL, Vol. 35 (pp 1031-1032)
- TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS. Journal of the American College of Cardiology, Vol. 63(12) (pp A25-A25)
- ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL. Journal of the American College of Cardiology, Vol. 63(12) (pp A18-A18)
- RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL. Journal of the American College of Cardiology, Vol. 63(12) (pp A298-A298)
- CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS: Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial. CIRCULATION, Vol. 128(22)
- Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? - A Report From the Plato Gwas Study. CIRCULATION, Vol. 128(22)
- Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome. CIRCULATION, Vol. 128(22)
- Morphine Delays the Onset of Action of Prasugrel in Patients With Prior History of St Elevation Myocardial Infarction. CIRCULATION, Vol. 128(22)
- Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease. CIRCULATION, Vol. 128(22)
- Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study. CIRCULATION, Vol. 128(22)
- Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment - a substudy from the prospective randomized PLATelet inhibit. PHARMACOTHERAPY, Vol. 33(10) (pp E189-E189)
- Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study. EUROPEAN HEART JOURNAL, Vol. 34 (pp 826-826)
- Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 34 (pp 827-827)
- Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose. EUROPEAN HEART JOURNAL, Vol. 34 (pp 891-891)
- GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study. EUROPEAN HEART JOURNAL, Vol. 34 (pp 733-733)
- Health economic evaluation of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes intended for non-invasive management based on the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 34 (pp 896-896)
- Hypoglycemia Increases Platelet Reactivity in Patients With Type 2 Diabetes. DIABETES, Vol. 62 (pp A100-A100)
- YIA6: VESSEL WALL, BUT NOT PLATELET, P2Y12 CONTRIBUTES TO EARLY ATHEROGENESIS. Heart, Vol. 99(suppl 2) (pp A7-A7)
- PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION. HEART, Vol. 99
- THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS. Journal of the American College of Cardiology, Vol. 61(10) (pp E1858-E1858)
- TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL. Journal of the American College of Cardiology, Vol. 61(10) (pp E1-E1)
- A study of a preoperative intervention in patients with diabetes undergoing cardiac surgery. DIABETIC MEDICINE, Vol. 30 (pp 152-152)
- ZEBRAFISH AS A MODEL TO INVESTIGATE THE ROLES OF THE P2Y12 RECEPTOR IN VIVO. ATHEROSCLEROSIS, Vol. 225(2) (pp E1-E1)
- Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes. Results from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 311-311)
- Vorapaxar in ACS patients undergoing CABG surgery: results from the TRACER trial. EUROPEAN HEART JOURNAL, Vol. 33 (pp 508-509)
- Contemporary pre-hospital management of ACS patients: results from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 314-314)
- Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients. EUROPEAN HEART JOURNAL, Vol. 33 (pp 135-135)
- Availability of cath lab facilities and contemporary inter-hospital transfer patterns for the management of ACS patients: findings from the EPICOR study. EUROPEAN HEART JOURNAL, Vol. 33 (pp 145-145)
- GREATER EFFICACY OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME IS NOT DRIVEN BY OUTCOMES IN POOR METABOLIZERS OF CLOPIDOGREL. Journal of the American College of Cardiology, Vol. 59(13) (pp E500-E500)
- PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E351-E351)
- REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY. Journal of the American College of Cardiology, Vol. 59(13) (pp E504-E504)
- USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E497-E497)
- PRIOR SMOKING STATUS, CLINICAL OUTCOMES, AND THE COMPARISON OF TICAGRELOR WITH CLOPIDOGREL IN ACUTE CORONARY SYNDROMES – INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E495-E495)
- RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E629-E629)
- TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 59(13) (pp E507-E507)
- REDUCTION IN PULMONARY ADVERSE EVENTS AND ASSOCIATED SEPSIS AND MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH TICAGRELOR COMPARED TO CLOPIDOGREL: A POST HOC ANALYSIS OF THE PLATO STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 59(13) (pp E482-E482)
- CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 59(13) (pp E505-E505)
- Cytochrome P450 2C19 Loss-Of-Function Genetic Variants but not Paraoxonase-1 Activity Modulate P2Y12 Blockade in Response to Clopidogrel Therapy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 58(20) (pp B45-B45)
- ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 57(14) (pp E946-E946)
- TICAGRELOR VERSUS CLOPIDOGREL IN ELDERLY PATIENTS WITH ACUTE CORONARY SYNDROMES: A SUBANALYSIS FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL. Journal of the American College of Cardiology, Vol. 57(14) (pp E1099-E1099)
- CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS). Journal of the American College of Cardiology, Vol. 57(14) (pp E999-E999)
- Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO. CIRCULATION, Vol. 122(21)
- Relationship between ATP hydrolysis and molecular dynamics in co-freeze-dried sugar-ATP mixtures. JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol. 62(10) (pp 1465-1467)
- Earlier recovery of platelet function after treatment cessation in ticagrelor-treated patients compared to clopidogrel high responders. EUROPEAN HEART JOURNAL, Vol. 31 (pp 389-389)
- Platelet inhibition by ticagrelor is not affected by proton pump inhibitors: results from the PLATO PLATELET substudy. EUROPEAN HEART JOURNAL, Vol. 31 (pp 905-906)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes and diabetes in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 31 (pp 202-202)
- Increased incidence of dyspnoea associated with ticagrelor did not appear to adversely affect cardiovascular outcomes in the PLATO study. EUROPEAN HEART JOURNAL, Vol. 31 (pp 203-203)
- Ticagrelor versus clopidogrel in patients with Acute Coronary Syndromes intended for a non-invasive management in the PLATO trial. EUROPEAN HEART JOURNAL, Vol. 31 (pp 203-203)
- The Effect of Ticagrelor on Cardiopulmonary Function in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1145-S1145)
- The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study. CIRCULATION, Vol. 120(18) (pp S1173-S1173)
- Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1102-S1102)
- More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. CIRCULATION, Vol. 120(18) (pp S1102-S1102)
- A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease. CIRCULATION, Vol. 120(18) (pp S1143-S1143)
- Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy. CIRCULATION, Vol. 120(18) (pp S1027-S1027)
- PLATO-Invasive: Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes with a planned invasive strategy: Results of the PLATelet inhibition and patient Outcomes (PLATO) trial. AMERICAN JOURNAL OF CARDIOLOGY, Vol. 104(6A) (pp XVIII-XVIII)
- RIFAMPICIN INCREASES THE EXTENT OF P2Y12 RECEPTOR BLOCKADE ACHIEVED BY CLOPIDOGREL ADMINISTRATION. HEART, Vol. 95 (pp A51-A52)
- High-performance liquid chromatography method development for studying the degradation of freeze-dried adenosine triphosphate when stored at 4 and 40 degrees C. JOURNAL OF PHARMACY AND PHARMACOLOGY, Vol. 61 (pp A130-A130)
- Rifampicin increases the extent of P2Y12 receptor blockade achieved by clopidogrel administration. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 7 (pp 105-105)
- Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 7 (pp 942-942)
- New developments in antiplatelet therapy. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 10(D) (pp D30-D37)
- The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 51(10) (pp A291-A291)
- Variability of response to antiplatelet therapy. EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol. 10(A) (pp A21-A27)
- Inhibition of platelet aggregation by clopiclogrel is unaffected by the CYP2C19 681G > A polyrnorphism in patients with coronary artery disease. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 49(9) (pp 375A-375A)
- AZD6140 exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. CIRCULATION, Vol. 114(18) (pp 698-699)
- AZD6140, a reversible oral ADP receptor antagonist, does not increase risk of bleeding vs the thienopyridine clopidogrel in patients undergoing CABG surgery in the DISPERSE2 trial. AMERICAN JOURNAL OF CARDIOLOGY, Vol. 98(8A) (pp 204M-204M)
- The G allele of the platelet P2Y1 1622 A > G polymorphism is not associated with platelet hyper-reactivity to ADP in either healthy volunteers or CAD patients. EUROPEAN HEART JOURNAL, Vol. 27 (pp 756-756)
- The P2Y12 receptor regulates the vessel wall response to arterial injury and thrombosis. EUROPEAN HEART JOURNAL, Vol. 27 (pp 753-753)
- The P2Y12 receptor regulates the vessel wall response to arterial injury and thrombosis. HEART, Vol. 92 (pp A111-A111)
- Platelet protease-activated receptor 1 density, trap-induced platelet responses, and the effect of complete P2Y(12) receptor blockade. HEART, Vol. 92 (pp A111-A112)
- The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 200A-200A)
- Clinical outcomes with AZD6140, an oral reversible ADP receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 199A-200A)
- Greater inhibition of platelet aggregation be tolerated? - Evaluation of the bleeding risk of AZD6140 compared with clopidogrel (CLOP) in patients with acute coronary syndromes (ACS). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 212A-212A)
- AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 204A-204A)
- AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol. 47(4) (pp 204A-204A)
- The DISPERSE2 trial: Safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndrome. CIRCULATION, Vol. 112(17) (pp U677-U677)
- Common sequence variations in the P2Y12 and CYP3A5 genes do not explain variability in the inhibitory effects of clopidogrel therapy. EUROPEAN HEART JOURNAL, Vol. 26 (pp 486-486)
- Partial P2Y12 receptor blockade by clopidogrel may not be overcome by increasing the clopidogrel dose. EUROPEAN HEART JOURNAL, Vol. 26 (pp 487-487)
- A randomized double blind comparison of two strategies for managing patients on aspirin and clopidogrel therapy requiring urgent coronary revascularization. CIRCULATION, Vol. 110(17) (pp 356-356)
- Gene sequence variations influence platelet reactivity before and during clopidogrel therapy. EUROPEAN HEART JOURNAL, Vol. 25 (pp 237-237)
- Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. HEART, Vol. 90 (pp A31-A31)
- Effects of clopidogrel on platelet calcium mobilisation in acute coronary syndrome patients. EUROPEAN HEART JOURNAL, Vol. 24 (pp 323-323)
- Effect of clopidogrel on procoagulant activity in acute coronary syndromes: Evidence for incomplete P2Y12 receptor blockade. CIRCULATION, Vol. 106(19) (pp 149-150)
- Inhibition of ADP-induced platelet-leukocyte conjugate formation by clopidogrel and AR-C69931MX. EUROPEAN HEART JOURNAL, Vol. 23 (pp 722-722)
- Clinical experience with antithrombotic drugs acting on purine receptor pathways. DRUG DEVELOPMENT RESEARCH, Vol. 52(1-2) (pp 202-212)
Other
- Response to letter regarding article, "ticagrelor in patients with acute coronary syndromes and stroke: Interpretation of subgroups in clinical trials". Stroke, 44(8).
Preprints
- Research group
-
PhD Students
- Dr William Parker
- Dr Wael Sumaya
MD Students
- Dr Rachel Orme
- Dr Vatchsala Sree Varadharajan
- Teaching activities
-
I am currently coordinator for the first year medical undergraduate Cardiovascular System module.
- Professional activities and memberships
-
- 2019: Research of the Year award, British Cardiovascular Intervention Society.
- 2017: Member of the BHF Fellowships Committee.
- 2015-2019: Member of the NIHR EME board.
- 2000: DM with distinction, 'Novel platelet antagonists in the management of ischaemic heart disease', University of Nottingham.
- 1999: Young Investigators Award, International Society of Thrombosis and Haemostasis.